4.6 unit (±5.5) reduction in Total Chorea Scores at Week 80 compared with baseline
Mean daily doses at Week 8 -- was 63.4 mg
After washout, Week 81, total chorea scores returned to baseline2
Adverse events experienced during the open-label extension were similar to those seen in the pivotal study. When mild and unrelated AEs were excluded, the most commonly reported AEs with Xenazine compared to placebo were sedation/somnolence (31% vs 3%), fatigue (22% vs 13%), insomnia (22% vs 0%), depression (19% vs 0%), akathisia (19% vs 0%), anxiety (15% vs 3%), and nausea (13% vs 7%).2
80-week, open-label extension of patients who completed the 12-week pivotal study (N=75)
The initial Xenazine® (tetrabenazine) protocol consisted of a total of 24 weeks, with 12 weeks of titration and 12 weeks of maintenance
XENAZINE® (tetrabenazine) Tablets
Indications and Usage:
XENAZINE is indicated for the treatment of chorea associated with Huntington’s disease.
Important Safety Information:
For more information, please see the full Prescribing Information, including Boxed Warning, the Medication Guide or go to www.XENAZINEusa.com.
Xenazine is a registered trademark of Valeant International Bermuda or its affiliates.
©2017 Lundbeck, Deerfield, IL 60015. All rights reserved.
The product information provided in this site is intended only for residents of the U.S. The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider.